Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.
We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-alpha (IFN-alpha). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN-alpha and bestatin. Although the precise mechanism by which remission was induced is uncertain, a GVL effect combined with a direct antileukemia effect of IFN-alpha may be responsible. Further assessment of the role of IFN-alpha in relapsed JMLL patients is warranted.
Ohta
H
H
Department of Developmental Medicine (Pediatrics), Osaka Utniversihv Graduate School of Medicine, Suita, Japan.
Kawai
M
M
Sawada
A
A
Tokimasa
S
S
Fujisaki
H
H
Matsuda
Y
Y
Osugi
Y
Y
Okada
S
S
Hara
J
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D003131:Combined Modality Therapy; D020544:Graft vs Leukemia Effect; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy / Q000628:therapy*; D008297:Male
D000970:Antineoplastic Agents; D016898:Interferon-alpha